MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Effects of a Parkinson-Specific, Interdisciplinary Approach, To Inpatient Rehabilitation

    C. Benedict, D. Fredericks, C. Manganiello, H. Herrstrom, D. Schmitt, K. Lyons (Topeka, KS, USA)

    Objective: To demonstrate the effects of an interdisciplinary team approach in the evaluation and treatment of Parkinson’s disease (PD) patients, during inpatient rehabilitation. Background:  PD…
  • 2017 International Congress

    Antiparkinson and antioxidant effect of N-Methanesulfonylpyrazolinyl substituted Heterosteroids in LPS induced Neuroinflammation Model of Rats

    R. Singh (Chandigarh, India)

    Objective: This present study is mainly focused at design and synthesis of new therapeutically useful steroidal neuroprotective agents against neuroinflammation which involved in the progression…
  • 2017 International Congress

    Active Arms: a randomized controlled trial of an interactive videogame for people with Parkinson’s disease

    N. Allen, J. Song, S. Paul, S. Smith, J. O'Duffy, M. Schmidt, R. Love, C. Sherrington, C. Canning (Lidcombe, Australia)

    Objective: To determine if home-based exergames targeting the upper extremities (UE) improves arm and hand activities and impairments in people with PD. To establish the…
  • 2017 International Congress

    Study Design of an Efficacy and Safety Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of APL-130277 in the Treatment of OFF Episodes (CTH-300)

    C.W. Olanow, E. Pappert, P. Gardzinski, B. Dzyngel, A. Agro (New York, NY, USA)

    Objective: To review the unique features of the ongoing Phase 3 trial for APL-130277.  Background: Patients with Parkinson’s disease (PD) frequently develop problematic OFF episodes…
  • 2017 International Congress

    Noladin ether attenuates MPTP -induced motor deficit by abrogating pro-inflammatory cytokines and striatal neurochemical alterations in rats

    R. Deshmukh, S. Singh (Moga, India)

    Objective: The present study was designed to investigate the therapeutic potential of noladin ether- a putative endocannabinoid against MPTP-induced behavioral, biochemical and neurochemical alterations in…
  • 2017 International Congress

    Nilotinib differentially affects oligomeric α-synuclein and reduces phosphorylated neurofilaments and motor symptoms in Parkinson’s disease with dementia and Lewy body dementia

    F. Pagan, M. Hebron, Y. Torres-Yaghi, A. Lawler, T. Kimbason, N. Starr, B. Wilmarth, M. Arellano, A. Shekoyan, J. Ahn, C. Moussa (Washington, DC, USA)

    Objective: This is a retrospective biomarker study of an open-label clinical study to examine the safety and efficacy of lower doses (<50% of CML dose)…
  • 2017 International Congress

    A single aerobic exercise session of treadmill increases BDNF levels in Parkinson’s disease patients

    P. Scalzo, L. Dos Santos, J. Pereira, R. Santos, N. Rocha, A. Texeira, P. Christo (Belo Horizonte, Brazil)

    Objective: The aim of this study was to investigate the effect of a single session moderate-intensity treadmill exercise on serum levels brain-derived neurotrophic factor (BDNF)…
  • 2017 International Congress

    Slow Release Fixed Dose Combination of Low Doses Pramipexole and Rasagiline (P2B001) for the Treatment of Early Parkinson’s Disease (PD).

    C. Olanow, K. Kieburtz, N. Livnah (New York, NY, USA)

    Objective: Evaluation of the efficacy and safety of a slow release low dose combination of pramipexole (PPX) and rasagiline (RAS) (P2B001) in a prospective double-blind…
  • 2017 International Congress

    Vitamin D and Clinical Phenotypes of Parkinson’s Disease

    F. Jamal, G. Jackson, S. Moore, A. Sarwar (Houston, TX, USA)

    Objective: To explore the relationship of clinical phenotypes of Parkinson's disease (PD) with vitamin D levels in Veterans diagnosed with PD. Background: PD is a heterogeneous neurodegenerative…
  • 2017 International Congress

    Istradefylline for daytime sleepiness and sleep disturbances in patients with Parkinson’s disease: an open-label, 3-month study

    K. Suzuki, M. Miyamoto, T. Miyamoto, T. Uchiyama, Y. Watanabe, T. Kadowaki, K. Hirata (Mibu, Japan)

    Objective: To evaluate the effect of istradefylline on daytime sleepiness and sleep disturbances as well as motor symptoms in patients with Parkinson’s disease (PD) in…
  • « Previous Page
  • 1
  • …
  • 1501
  • 1502
  • 1503
  • 1504
  • 1505
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley